Allergies Cardiology Doctors Trials 
Velocity Clinical Research
JANUARY 3, 2024
The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. In most cases, the participant of a clinical trial benefits from taking part, which is of great importance, especially in oncological trials.
The Pharma Data
NOVEMBER 4, 2020
Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.
Expert insights. Personalized for you.
52 
Let's personalize your content